The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24 ‐mediated mechanism
Cancer Science · 2024
DOI: 10.1111/cas.16191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Shinpei Saito und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Large Neutral Amino Acid-Transporter 1, Cell Proliferation, CD24 Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Foundation for Promotion of Material Science and Technology of Japan.
Abstract (Originalsprache)
L‐type amino acid transporter 1 (LAT1) is specifically expressed in many malignancies, contributes to the transport of essential amino acids, such as leucine, and regulates the mammalian target of rapamycin (mTOR) signaling pathway. We investigated the expression profile and functional role of LAT1 in prostate cancer using JPH203, a specific inhibitor of LAT1. LAT1 was highly expressed in castration‐resistant prostate cancer (CRPC) cells, including C4‐2 and PC‐3 cells, but its expression level was low in castration‐sensitive LNCaP cells. JPH203 significantly inhibited [ 14 C] leucine uptake in CRPC cells but had no effect in LNCaP cells. JPH203 inhibited the proliferation, migration, and invasion of CRPC cells but not of LNCaP cells. In C4‐2 cells, Cluster of differentiation (CD) 24 was identified by RNA sequencing as a novel downstream target of JPH203. CD24 was downregulated in a JPH203 concentration‐dependent manner and suppressed activation of the Wnt/β‐catenin signaling pathway. Furthermore, an in vivo study showed that JPH203 inhibited the proliferation of C4‐2 cells in a castration environment. The results of this study indicate that JPH203 may exert its antitumor effect in CRPC cells via mTOR and CD24.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Bio-System Pharmacology, Osaka University Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Shinichi Sakamoto, Yasutaka Yamada, Junryo Rii, Yoshikatsu Kanai, Naohiko Anzai
Förderung
- Foundation for Promotion of Material Science and Technology of Japan
Zitieren
APA
Saito, S., Ando, K., Sakamoto, S., Xu, M., Yamada, Y., Rii, J., Kanaoka, S., Wei, J., Zhao, X., Pae, S., Kanesaka, M., Goto, Y., Sazuka, T., Imamura, Y., Reien, Y., Hamaguchi-Suzuki, N., Saito, S., Hirayama, Y., Hashimoto, H., …, & Anzai, N. (2024). The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24 ‐mediated mechanism. Cancer Science. https://doi.org/10.1111/cas.16191
Vancouver
Saito S, Ando K, Sakamoto S, Xu M, Yamada Y, Rii J, et al. The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24 ‐mediated mechanism. Cancer Science. 2024. doi:10.1111/cas.16191
BibTeX
@article{Saito2024,
author = {Saito, Shinpei and Ando, Keisuke and Sakamoto, Shinichi and Xu, Minhui and Yamada, Yasutaka and Rii, Junryo and Kanaoka, Sanji and Wei, Jiaxing and Zhao, Xue and Pae, Sangjon and Kanesaka, Manato and Goto, Yusuke and Sazuka, Tomokazu and Imamura, Yusuke and Reien, Yoshie and Hamaguchi-Suzuki, Norie and Saito, Shota and Hirayama, Yuri and Hashimoto, Hirofumi and Kanai, Yoshikatsu and Ichikawa, Tomohiko and Anzai, Naohiko},
title = {The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24 ‐mediated mechanism},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16191}
}
EUVIMED